1
|
Long Y, Huang C, Cui Y, Xie Z, Zhou Y, Shi X, Song Y, Tian X, Li M, Liu J, Liu X, Zeng X, Zhao J. Cluster analysis of antiphospholipid antibodies-associated adverse pregnancy outcome patients: based on a 13-years cohort study. Clin Exp Med 2023; 23:5377-5388. [PMID: 37821708 DOI: 10.1007/s10238-023-01195-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2023] [Accepted: 09/12/2023] [Indexed: 10/13/2023]
Abstract
Antiphospholipid antibodies (aPLs) are the leading causes of adverse pregnancy outcomes (APOs). We conducted cluster analysis to identify distinct phenotypes among aPLs-associated APOs patients. This approach aims to facilitate risk stratification and improve pregnancy outcomes for obstetric APS. This was a retrospective study of persistent aPLs positive women cohort in Peking Union Medical College Hospital. Baseline demographic characteristics, clinical manifestation, previous APOs and antibodies profiles were included for hierarchical cluster analysis. Placentae from portions of patients were collected and performed the histopathologic diagnoses. Four clusters among 209 patients with 477 pregnancies were identified. Cluster 1 comprised patients with triple aPLs positivity and demonstrates a high incidence of gestational hypertension (34.92%, P < 0.05) and preterm delivery (20.63%, P < 0.05). Patients in cluster 2 were characterized by lupus anticoagulant (LA) positivity, with high risk of whole gestational APOs. Cluster 3 included patients with isolated aPLs-IgM isotype combined with early miscarriage (60.92%, P = 0.016). Patients in cluster 4 majorly presented aPLs-IgG isotype combined with placenta insufficiency (22.73%). During the follow-up, the live birth rate in cluster 1 and 2 was only 69.20%. Placenta pathology revealed the most severe impairment within cluster 1, whereas clusters 3 and 4 exhibited relatively milder damage. By cluster analysis, we identified four clinical subtypes of aPLs-associated APOs patients. Patients with triple antibodies or high-risk lupus characteristics were prone to occurred gestational hypertension and premature delivery. Isolated LA or aCL/aβ2GPI positivity were found to be more frequently associated with early-stage fetal loss.
Collapse
Affiliation(s)
- Yin Long
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
| | - Can Huang
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
| | - Yixin Cui
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
| | - Zhijuan Xie
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
| | - Yangzhong Zhou
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
| | - Xiaohua Shi
- Department of Pathology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - Yijun Song
- Department of Obstetrics, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
| | - Xinping Tian
- National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
| | - Mengtao Li
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
- Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
| | - Juntao Liu
- Department of Obstetrics, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China
| | - Xinyan Liu
- Department of Obstetrics, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China.
| | - Xiaofeng Zeng
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China.
- National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China.
- Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China.
- Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China.
| | - Jiuliang Zhao
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China.
- National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China.
- Ministry of Science and Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China.
- Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No. 1 Shuai Fu Yuan, Wangfu Jing Street, Beijing, 100730, China.
| |
Collapse
|
2
|
Xu J, Yang C, Zeng S, Wang X, Yang P, Qin L. Disturbance of neuron-microglia crosstalk mediated by GRP78 in Neuropsychiatric systemic lupus erythematosus mice. J Neuroinflammation 2023; 20:150. [PMID: 37365565 DOI: 10.1186/s12974-023-02832-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2023] [Accepted: 06/12/2023] [Indexed: 06/28/2023] Open
Abstract
OBJECTIVES Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious phenotype of systemic lupus erythematosus (SLE). The disturbance of neuron-microglia crosstalk is recently revealed in many neuropsychiatric diseases but was not well studied in NPSLE. We found glucose regulatory protein 78 (GRP78), a marker of endoplasmic reticulum stress, was significantly increased in the cerebrospinal fluid (CSF) of our NPSLE cohort. We, therefore, investigated whether GRP78 can act as a mediator between the neuron-microglia crosstalk and is involved in the pathogenic process of NPSLE. METHODS Serum and CSF parameters were analyzed in 22 NPSLE patients and controls. Anti-DWEYS IgG was injected intravenously into mice to establish a model of NPSLE. Behavioral assessment, histopathological staining, RNA-seq analyses, and biochemical assays were performed to examine the neuro-immunological alterations in the mice. Rapamycin was intraperitoneally administered to define the therapeutic effect. RESULTS The level of GRP78 was elevated significantly in the CSF of the patients with NPSLE. An increase in GRP78 expression, accompanied by neuroinflammation and cognitive impairment, was also found in the brain tissues of the NPSLE model mice induced by anti-DWEYS IgG deposition on hippocampal neurons. In vitro experiments demonstrated that anti-DWEYS IgG could stimulate neurons to release GRP78, which activated microglia via TLR4/MyD88/NFκB pathway to produce more pro-inflammatory cytokines and promote migration and phagocytosis. Rapamycin ameliorated GRP78-inducing neuroinflammation and cognitive impairment in anti-DWEYS IgG-transferred mice. CONCLUSION GRP78 acts as a pathogenic factor in neuropsychiatric disorders via interfering neuron-microglia crosstalk. Rapamycin may be a promising therapeutic candidate for NPSLE.
Collapse
Affiliation(s)
- Jingyi Xu
- Department of Rheumatology and Immunology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China
| | - Chunshu Yang
- Department of 1st Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China
| | - Siyuan Zeng
- Department of Rheumatology and Immunology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China
| | - Xuejiao Wang
- Department of Physiology, School of Life Science, China Medical University, Shenyang, Liaoning Province, 110122, People's Republic of China
| | - Pingting Yang
- Department of Rheumatology and Immunology, The First Hospital of China Medical University, Shenyang, 110001, People's Republic of China.
| | - Ling Qin
- Department of Physiology, School of Life Science, China Medical University, Shenyang, Liaoning Province, 110122, People's Republic of China.
| |
Collapse
|
3
|
Ye H, Liu S, Xu J, Chai K, He D, Fang Y, Xie Q, Liu H, Liu Y, Hua B, Hu J, Zhang Z, Zhou M, Zhao D, Li Y, Jiang Z, Wang M, Li J, Zhang Z, Li X, Li Y, Sun E, Bi L, Wei W, Tie N, He L, Huang X, Zhang Y, Huang Q, Wang X, Liu X, Li J, Su Y. Efficacy and Safety of CMAB008 Compared with Innovator Infliximab in Patients with Moderate-to-Severe Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Randomized, Double-blind, Multi-center, Phase III Non-inferiority Study. Rheumatol Ther 2023; 10:757-773. [PMID: 36964872 PMCID: PMC10140208 DOI: 10.1007/s40744-023-00544-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 02/20/2023] [Indexed: 03/26/2023] Open
Abstract
OBJECTIVES The aim of this work is to verify the non-inferior efficacy and safety of CMAB008 compared with innovator infliximab in rheumatoid arthritis patients combined with methotrexate. METHODS We conducted a randomized, double-blinded, parallel, positive control design, multicenter study, with a stable dose of methotrexate. Patients were enrolled randomly with a ratio of 1:1 to receive intravenously CMAB008 3 mg/kg or innovator infliximab 3 mg/kg at weeks 0, 2, 6, 14, 22 and 30. The primary efficacy endpoint was American College of Rheumatology 20% improvement criteria (ACR20) response rate at week 30. The non-inferiority was established if the lower limit of the one-sided 97.5% confidence interval (CI) for the difference was more than - 15% and the equivalence was established if the two-sided 95% CI was within ± 15% in an exploratory equivalence analysis. The secondary endpoints included other efficacy assessment parameters, as well as immunogenicity, safety, and pharmacokinetics. RESULTS In the full analysis population (FAS), 110 (57.6%) of 191 patients in the CMAB008 group and 120 (62.2%) of 193 patients in the innovator infliximab group reached the primary outcome of ACR20 at week 30. The differences of the rates were - 4.6% and the lower limit of one-sided 97.5% confidence interval was - 14.29%, not less than the lower limit of the non-inferiority margin (- 15%); so CMAB008 was non-inferior to innovator infliximab. Further, CMAB008 was equivalent to innovator infliximab both in FAS (difference - 4.6%, 95% CI - 14.29% to 5.12%) and PPS (difference - 3.3%, 95% CI - 13.18% to 6.62%). The efficacy, safety, immunogenicity, and pharmacokinetics are highly similar between CMAB008 and innovator infliximab. CONCLUSIONS Non-inferior efficacy of CMAB008 to innovator infliximab is illustrated with similar early and lasting therapeutic effects, and the equivalence is further demonstrated. CMAB008 is well tolerated and has semblable safety compared with the innovator infliximab. TRIAL REGISTRATION NUMBER NCT03478111.
Collapse
Affiliation(s)
- Hua Ye
- Rheumatology Department, Peking University People's Hospital, No. 11, XiZhimen South Street, Beijing, 100044, China
| | - Shengyun Liu
- Rheumatology and Immunology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Jian Xu
- Rheumatology and Immunology Department, First Affiliated Hospital of Kunming Medical University, Kunming, China
| | - Kexia Chai
- Rheumatology and Immunology Department, Qinghai University Affiliated Hospital, Xining, China
| | - Dongyi He
- Arthrology Department, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, China
| | - Yongfei Fang
- Rheumatology and Immunology Department of Traditional Chinese Medicine, The Southwest Hospital of Army Medical University, Chongqing, China
| | - Qibing Xie
- Rheumatology and Immunology Department, West China Hospital Sichuan University, Chengdu, China
| | - Huaxiang Liu
- Department of Rheumatology, Qilu Hospital of Shandong University, Jinan, China
| | - Ying Liu
- Rheumatology and Immunology Department of Traditional Chinese Medicine, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Bingzhu Hua
- Rheumatology and Immunology Department, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China
| | - Jiankang Hu
- Rheumatology and Immunology Department, Pingxiang People's Hospital, Pingxiang, China
| | - Zhiyi Zhang
- Rheumatology and Immunology Department, The First Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Mingxuan Zhou
- Immunology Department, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
| | - Dongbao Zhao
- Rheumatology and Immunology Department, Changhai Hospital of Shanghai, Shanghai, China
| | - Yan Li
- Rheumatology and Immunology Department, The First Affiliated Hospital of Xiamen University, Xiamen, China
| | - Zhenyu Jiang
- Rheumatology and Immunology Department, The First Hospital of Jilin University, Changchun, China
| | - Meimei Wang
- Rheumatology and Immunology Department, Zhongda Hospital Southeast University, Nanjing, China
| | - Jingyang Li
- Rheumatology and Immunology Department, Zhuzhou Central Hospital, Zhuzhou, China
| | - Zhuoli Zhang
- Rheumatology and Immunology Department, Peking University First Hospital, Beijing, China
| | - Xiaomei Li
- Rheumatology and Immunology Department, Anhui Provincial Hospital, Hefei, China
| | - Yang Li
- Rheumatology and Immunology Department, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
| | - Erwei Sun
- Rheumatology and Immunology Department, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China
| | - Liqi Bi
- Rheumatology and Immunology Department, China-Japan Union Hospital of Jilin University, Changchun, China
| | - Wei Wei
- Rheumatology and Immunology Department, Tianjin Medical University General Hospital, Tianjin, China
| | - Ning Tie
- Rheumatology and Immunology Department, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot City, China
| | - Lan He
- Rheumatology and Immunology Department, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Xiangyang Huang
- Rheumatology and Immunology Department, The Second Xiangya Hospital of Central South University, Changsha, China
| | - Yan Zhang
- Rheumatology and Immunology Department, The Second Affiliated Hospital, Tangdu Hospital The Air Force Military Medical University, Xi'an, China
| | - Qingchun Huang
- Rheumatology Department, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
| | - Xiaofei Wang
- Rheumatology and Immunology Department, Shengjing Hospital of China Medical University, Shenyang, China
| | - Xiangyuan Liu
- Rheumatology and Immunology Department, Peking University Third Hospital, Beijing, China
| | - Jing Li
- Mabpharm Limited, Taizhou, China
| | - Yin Su
- Rheumatology Department, Peking University People's Hospital, No. 11, XiZhimen South Street, Beijing, 100044, China.
| |
Collapse
|